1. Sulforaphane inhibits the activation of hepatic stellate cell by miRNA-423-5p targeting suppressor of fused.
- Author
-
Feng MH, Li JW, Sun HT, He SQ, and Pang J
- Subjects
- Cell Line, Depression, Chemical, Down-Regulation drug effects, Humans, Isothiocyanates therapeutic use, Liver Cirrhosis drug therapy, MicroRNAs genetics, Molecular Targeted Therapy, Sulfoxides, Cell Survival drug effects, Cell Survival genetics, Hepatic Stellate Cells physiology, Isothiocyanates pharmacology, Liver Cirrhosis etiology, Liver Cirrhosis genetics, MicroRNAs metabolism
- Abstract
Liver fibrosis, a common pathological process in chronic liver diseases, is characterized by excessive accumulation of extracellular matrix proteins and considered as a wound healing response to chronic liver injury. Hepatic stellate cell (HSC) activation plays a key role in liver fibrosis development. Previous studies showed that sulforaphane (SFN) has wide protective effects against tissue injury and inflammation. Accumulating evidence has shown that microRNAs play important roles in the development of hepatic fibrosis, some of which have been identified as potential therapeutic targets. This study was conducted to explore the role of SFN in the suppression of HSC activation. Quantitative real-time PCR showed that HSC miR-423-5p levels were up-regulated during HSC activation and down-regulated after SFN administration. Further, transfection of a miR-423-5p mimic demonstrated that inhibition of HSC activation by SFN required down-regulation of miR-423-5p. We showed that suppressor of fused is the direct target of miR-423-5p. SFN may play a role in inhibiting hepatic fibrosis by downregulating miRNA-423-5p. MiRNA-423-5p may be useful as a therapeutic target for treating hepatic fibrosis.
- Published
- 2019
- Full Text
- View/download PDF